Our Commitment
Adamas develops novel therapeutics for the treatment of central nervous system (CNS) disorders. About Adamas
Product Pipeline
Product Pipeline
We have developed a portfolio of CNS therapeutics. Our Pipeline
ADS-5102 in LID
Why Aminoadamantanes?
Phase 3 program for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease. Learn More
Clinical Trials
Clinical Trials: LID in Parkinson's
ADS-5102 in Phase 2 trial for impaired gait and other major symptoms in multiple sclerosis. Clinical Trials